Armistice Capital LLC boosted its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 19.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,000,000 shares of the company's stock after purchasing an additional 1,800,000 shares during the quarter. Armistice Capital LLC owned about 4.13% of Autolus Therapeutics worth $17,050,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $26,000. Barclays PLC lifted its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares in the last quarter. Invesco Ltd. lifted its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after buying an additional 11,381 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Autolus Therapeutics during the fourth quarter valued at approximately $85,000. Finally, Exchange Traded Concepts LLC lifted its position in Autolus Therapeutics by 67.2% during the first quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company's stock valued at $108,000 after buying an additional 28,127 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.
Autolus Therapeutics Price Performance
AUTL opened at $1.50 on Friday. The stock has a market capitalization of $399.21 million, a PE ratio of -1.79 and a beta of 1.90. The firm's fifty day moving average price is $2.22 and its 200 day moving average price is $1.86. Autolus Therapeutics PLC Sponsored ADR has a 12-month low of $1.11 and a 12-month high of $5.00.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. On average, equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on AUTL shares. Wells Fargo & Company reduced their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, July 21st. Finally, Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and an average target price of $9.12.
Read Our Latest Stock Report on Autolus Therapeutics
About Autolus Therapeutics
(
Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Read More
Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
